Collectively, the ARF6-based pathway driven by the ZEB1-EPB41L5 axis appears to account for almost half the population of breast cancer patients that survive for less than several years after diagnosis under current therapeutics. This evidence concerns the gene ZEB1 and breast carcinoma.